77 results found

This tax is an attempt to tackle the increasing overweight problem. A draft decree is under preparation.

On April 7, 2016, the French National Security Agency for Medicines and Health Products ("ANSM") launched a public consultation on a draft ministerial order setting out pharmacovigilance best practices.

In 2021, the French drug agency determined that the stocks of hundreds of specific pharmaceutical products must be maintained by pharmaceutical companies at a level equivalent to 4 months of coverage...

Facilities located in France where RMPU is stored on behalf of distribution companies also fall within the scope of the authorization/declaration requirement.

While the United States and many other countries wrestle with how plant-based products designed to substitute as meats should be labeled or otherwise described...

We've covered the French Sunshine Act, which requires French pharmaceutical companies to disclose their links to healthcare providers, extensively over the past few years.

A similar call also could be carried out for nanomaterials potentially present as residues.

After several years in which the Council of State had quashed multiple decisions on setting prices or reimbursement conditions...

La culture de la vigne est particulièrement liée aux conditions météorologiques. Le secteur viti-vinicole est donc l'un des premiers à être violemment touché par le...

In the latest round of the Merz v Viatris dispute over the alleged infringement of Merz’s MS drug dosing regime patent (drug brand name Fampyra), the UPC Paris Local Division...

La Loi n° 2025-268 du 24 mars 2025 d'orientation pour la souveraineté alimentaire et le renouvellement des générations en agriculture a introduit une dérogation au principe de spécialité...

Reed Smith’s Global Regulatory Enforcement Law Blog features a post on a recent decision by the French Supreme Administrative Court (Conseil d’Etat) that expands the scope of the French Sunshine Act.

From 3rd October 2013, the French High Health Authority was given authorisation to carry out medico-economic evaluations of pharmaceutical products and medical devices in France.

On March 4, 2026, Decree No. 2026-153 [1] ("Decree") was published, defining the procedures under which the Minister of Health may impose financial penalties on publishers of digital health services...

In 2023, the CNIL established a dedicated service for the economic analysis of issues related to personal data, with the aim of strengthening its expertise and informing its decisions through impact assessments...

At the end of 2017, the Lons-le-Saunier Criminal Court pronounced a conditional sentence for the first time in the context of the application of the anti-gifts law.

On 24 February 2015, the French Supreme Administrative Court (Conseil d’Etat) reached a landmark decision which significantly expands the scope of the so-called French Sunshine Act.